Unichem Laboratories Limited Stock price

Equities

UNICHEMLAB

INE351A01035

Pharmaceuticals

Delayed Bombay S.E. 06:00:51 2024-03-28 am EDT 5-day change 1st Jan Change
488.5 INR +1.90% Intraday chart for Unichem Laboratories Limited -3.03% +20.05%
Sales 2022 12.7B 152M Sales 2023 13.43B 161M Capitalization 20.35B 244M
Net income 2022 331M 3.97M Net income 2023 -2.02B -24.27M EV / Sales 2022 1.42 x
Net cash position 2022 236M 2.84M Net Debt 2023 1.29B 15.45M EV / Sales 2023 1.61 x
P/E ratio 2022
55.6 x
P/E ratio 2023
-10.1 x
Employees 2,894
Yield 2022
1.54%
Yield 2023
-
Free-Float 28.81%
More Fundamentals * Assessed data
Dynamic Chart
Unichem Laboratories Chief Commercial and International Business Development Officer Steps Down MT
Unichem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Indian Equities Close Marginally Higher Ahead of IT Earnings MT
Unichem Laboratories Gets US FDA Approval for Generic Hypertension Drug MT
Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg CI
Unichem Laboratories Completes Sale of Entire Stake in Optimus Drugs MT
Unichem Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Ipca Laboratories Limited completed the acquisition of 19.29% stake in Unichem Laboratories Limited for INR 6 billion. CI
Unichem Laboratories Gets US FDA Nod for Prasugrel Tablets MT
Unichem Laboratories Limited Receives ANDA Approval for its Prasugrel Tablets USP, 5 Mg and 10 Mg from the United States Food and Drug Administration CI
Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors CI
Ipca Laboratories Acquires 33% Stake in Unichem for INR9.45 Billion MT
Unichem Laboratories Trims Consolidated Net Loss in Fiscal Q1 MT
Unichem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Unichem Laboratories Swings to Loss in Fiscal Q4 MT
More news
1 day+1.90%
1 week-3.03%
Current month-6.26%
1 month-5.40%
3 months+20.65%
6 months+18.90%
Current year+20.05%
More quotes
1 week
473.00
Extreme 473
501.00
1 month
473.00
Extreme 473
534.10
Current year
416.30
Extreme 416.3
579.80
1 year
285.90
Extreme 285.9
579.80
3 years
197.50
Extreme 197.5
579.80
5 years
75.10
Extreme 75.1
579.80
10 years
75.10
Extreme 75.1
579.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 23-08-09
Director of Finance/CFO - 18-10-29
Chairman 71 77-08-21
Members of the board TitleAgeSince
Director/Board Member 86 78-12-31
Director/Board Member 71 05-10-16
Director/Board Member 51 23-08-09
More insiders
Date Price Change Volume
24-03-28 488.5 +1.90% 1,119
24-03-27 479.4 -1.67% 3,337
24-03-26 487.6 -1.54% 3,081
24-03-22 495.2 -1.70% 3,476
24-03-21 503.8 +2.20% 510

Delayed Quote Bombay S.E., March 28, 2024 at 06:00 am EDT

More quotes
Unichem Laboratories Limited is an India-based international, integrated, specialty pharmaceutical company. The Company is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. It manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. It has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The Company is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.
More about the company
  1. Stock
  2. Equities
  3. Stock Unichem Laboratories Limited - Bombay S.E.